A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)

Cryopyrin Associated Periodic Syndrome Clinical Trial

Official title:
A Phase 2a, Prospective, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)

Status Completed

Clinical Trial Summary

ZYIL1 is expected to show benefit in patients with CAPS. The present study aims to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 when administered to subjects with CAPS.

Clinical Trial Description

This is a phase 2a, prospective, open-label study. Primary objective of the study is to determine safety and tolerability profile of twice daily oral administration of ZYIL1 administered for 7 days. The study will be conducted in 3 subjects having CAPS as per eligibility criteria. The study will be divided in three periods: Screening Period; Run-in Period and Study Period. ;

Study Design

Related Conditions & MeSH terms

Cryopyrin Associated Periodic Syndrome
Cryopyrin-Associated Periodic Syndromes
Syndrome

Clinical Trial Details

NCT number	NCT05186051
Study type	Interventional
Source	Cadila Healthcare Limited
Contact
Status	Completed
Phase	Phase 2
Start date	June 1, 2022
Completion date	July 2, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04856540` - Adult Outcomes of Children With CAPS
Completed	`NCT04086602` - Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334	Phase 1
Not yet recruiting	`NCT05292768` - Are Mast Cells Involved in Autoinflammatory Diseases
Completed	`NCT05812781` - A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome	Phase 2
Completed	`NCT01105507` - The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada	Phase 3